Phase II Study With Decitabine (5-aza-2'-Deoxycytidine, DAC) in Myelodysplastic Syndromes
OBJECTIVES: I. Determine the response of patients with myelodysplastic syndromes (including
chronic myelomonocytic leukemia) to decitabine.
OUTLINE: This is an open label, multicenter study. Patients are stratified by disease (low
risk myelodysplastic syndrome (MDS) vs. high risk MDS vs. chronic myelomonocytic leukemia).
Patients receive decitabine as a 4 hour infusion every 8 hours on days 1-3. Treatment
continues every 6-8 weeks for 4-6 courses. Patients are followed at 6 and 12 months.
PROJECTED ACCRUAL: Approximately 75 patients will be accrued for this study over 1 year.
Interventional
Primary Purpose: Treatment
Stephen D. Nimer, MD
Study Chair
Memorial Sloan-Kettering Cancer Center
United States: Federal Government
MSKCC-98017
NCT00003361
April 1998
December 2009
Name | Location |
---|---|
Memorial Sloan-Kettering Cancer Center | New York, New York 10021 |
University of Texas - MD Anderson Cancer Center | Houston, Texas 77030-4009 |
Johns Hopkins Oncology Center | Baltimore, Maryland 21287 |